Fresenius Kabi AG - Company Profile
Powered by 
All the data and insights you need on Fresenius Kabi AG in one report.
$295
- Save hours of research time and resources with
our up-to-date Fresenius Kabi AG Strategy Report
- Understand Fresenius Kabi AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Fresenius Kabi AG (Fresenius Kabi), a subsidiary of Fresenius SE & Co KGaA, develops, manufactures, and commercializes pharmaceutical products and medical devices. Its product portfolio includes intravenously administered drugs, infusion therapy products, medical devices and clinical nutrition products. The company's therapeutic expertise covers areas of blood volume substitution, fluid management, anesthesia, critical illness, liver insufficiency, renal insufficiency, maldigestion or malabsorption, diabetes mellitus, and pediatrics. Its products and services are indicated for the treatment of critically and chronically ill patients. Fresenius Kabi conducts sales and marketing operations through direct offices worldwide. The company has facilities in Europe, North America, Latin America, Asia Pacific and Africa. Fresenius Kabi is headquartered in Bad Homburg, Germany
Headquarters
Germany
Address
Else-Kroner-Strasse 1, Bad Homburg, Hessen, 61352
Website
www.fresenius-kabi.com
Telephone
49 6172 6860
No of Employees
42,063
Industry
Medical Equipment
Revenue (2022)
$8.3B
Fresenius Kabi AG premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Infusion Therapy: | Transition Management: | Amicus |
| Blood Volume Substitutes / HES: | Home Therapy | Voluven |
| Volulyte 6% | Volulyte | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In October, the company launched +RFID smart labels for Diprivan (Propofol) injectable emulsion, USP, 200mg per 20ml in single-dose vials, in the US. |
| 2023 | Regulatory Approval | In September, the company received marketing authorization from the European Commission for its tocilizumab biosimilar Tyenne. |
| 2023 | New Products/Services | In July, the company launched biosimilar Idacio (adalimumab-aacf) in the US. |
Competitor Comparison
| Key Parameters | Fresenius Kabi AG | Abbott Laboratories | Becton Dickinson and Co | Teva Pharmaceutical Industries Ltd | Sandoz Inc |
|---|---|---|---|---|---|
| Headquarters | Germany | United States of America | United States of America | Israel | United States of America |
| City | Bad Homburg | Abbott Park | Franklin Lakes | Tel Aviv | Princeton |
| State/Province | Hessen | Illinois | New Jersey | Tel Aviv | New Jersey |
| No. of Employees | 42,063 | 114,000 | 73,000 | 35,001 | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pierluigi Antonelli | Chief Executive Officer | Senior Management | 2023 | 56 |
| Andreas Duenkel | Chief Financial Officer; Chief Compliance Officer | Senior Management | 2022 | - |
| Yvonne Albert | Chief Human Resources Officer | Senior Management | 2023 | - |
| Marc Crouton | President - Europe | Senior Management | - | - |
| Ulf Jansson | Executive Vice President - Asia Pacific | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward